Rheolytic thrombectomy market seen reaching $1.9 billion by 2030

The rheolytic thrombectomy market is projected to grow from $1.14 billion in 2025 to $1.26 billion in 2026, then reach $1.9 billion by 2030, according to The Business Research Company. The report points to rising cardiovascular disease, thrombotic disorders and an aging population as the main demand drivers.

Why it matters: - Rheolytic thrombectomy is becoming more important as hospitals and vascular centers look for faster ways to remove blood clots and restore blood flow. - The market’s growth signals rising demand for minimally invasive clot-removal tools in acute conditions such as deep vein thrombosis and pulmonary embolism.

What happened: - The Business Research Company published a forecast report on the rheolytic thrombectomy market on July 22, 2026. - The market is estimated at $1.14 billion in 2025 and projected to reach $1.26 billion in 2026. - The report forecasts the market will rise to $1.9 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - The forecast implies a 10.6% CAGR for 2025 to 2026 and a 10.9% CAGR through 2030. - The market’s recent growth is linked to more thrombotic disorders, higher cardiovascular disease prevalence, wider adoption of minimally invasive procedures, vascular intervention innovation and more specialized treatment centers. - The report says future growth will be driven by more deep vein thrombosis and pulmonary embolism cases, stronger demand for rapid clot removal, device advances, healthcare infrastructure investment and broader use of image-guided vascular interventions. - The report identifies several expected trends, including improved catheter-based clot removal, more efficient saline jet systems, faster revascularization techniques and expanded use in peripheral vascular interventions. - Rheolytic thrombectomy uses a high-velocity saline jet system to break up clots and suction away debris while restoring blood flow. - The procedure is used in urgent situations where immediate clot removal is critical. - The report cites cardiovascular disease as a major growth driver because rapid clot removal can reduce ischemic damage and improve recovery outcomes. - The report cites UK Joint Strategic Needs Assessment data showing 185 cardiovascular disease deaths in 2023, up from 178 in 2022. - The report cites NHS England data showing venous thromboembolism risk assessments covered 92% of admitted patients in the third quarter of 2025. - The World Health Organization said in February 2025 that the global population aged 60 and older is expected to rise from 1.1 billion in 2023 to 1.4 billion by 2030.

Between the lines: - The market outlook reflects a broader shift toward less invasive, faster vascular procedures that can be deployed in high-risk, time-sensitive cases. - Aging populations and rising clot-related disease are expanding the addressable patient pool, which helps explain why device makers and care providers are investing in this category. - North America’s lead suggests the region is already farther along in adopting advanced intervention technologies, while Asia-Pacific’s growth points to a wider rollout ahead.

What's next: - The report expects continued adoption of catheter-based and image-guided thrombectomy tools as clot-related disease remains a major clinical burden. - Growth in regional healthcare infrastructure and broader awareness of minimally invasive options are likely to support expansion through 2030. - The Business Research Company says its 2026 reports also include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspots infographics, and updated graphics and tables.

The bottom line: - Rheolytic thrombectomy is moving from a niche intervention toward a broader growth market, powered by more clot-related disease, aging demographics and demand for rapid, minimally invasive treatment.